ArticleAmerican journal of clinical and experimental immunology2019
Serum level measurement of progranulin in relapsing-remitting multiple sclerosis and neuromyelitis optica patients.
Article in American journal of clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis (MS) is a complex autoimmune disease of the central nervous system (CNS) with unknown etiology and variable clinical evolution. Although the role of serum progranulin levels in the pathogenesis of MS remains unclear, it is well known that progranulin is involved in several physiological and pathophysiological process of CNS including modulation of neurite outgrowth, neuronal differentiation, and neuronal survival. Therefore, in this study, we aimed to measure serum levels of progranulin in patients with neuromyelitis optica (NMO) and relapsing-remitting multiple sclerosis (RRMS) in comparison with healthy control subjects.
methodsIn a case-control study, plasma was collected from healthy controls (n = 37) and also patients with RRMS (n = 115) and NMO (n = 33). Serum level measurement of progranulin was performed using a sandwich ELISA method.
resultsThe serum levels of progranulin were 65.07 ± 11.64, 56.81 ± 10.34, and 47.73 ± 10.37 in NMO and MS patients and healthy controls, respectively, showing a statistically significant difference between them (P = 0.00). Furthermore, we found a positive correlation between serum levels of progranulin and EDSS of patients (r = 0.79 and P = 0.00).
conclusionThe present study demonstrated that progranulin is up-regulated in MS patients and our findings strengthen the evidence for progranulin being involved in the pathogenesis of MS. However, further studies will be required to establish progranulin as an important marker for MS.
Indexed as
Identifiers
31316865PMC6627460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.